Craft

Athenex

Stock Price

$0

2023-07-26

Market Capitalization

$2.3 M

2023-07-26

Revenue

$102.8 M

FY, 2022

Athenex Summary

Company Summary

Overview
Athenex is a biopharmaceutical company dedicated to the discovery and commercialization of therapies for the treatment of cancer. It operates medical technology innovation centers and a manufacturing supply chain. The company delivers proprietary medical technologies, including small molecule, biologic, and cellular therapies.
Type
Public
Status
Active
Founded
2003
HQ
Buffalo, NY, US | view all locations
Website
https://www.athenex.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Johnson Y.n. Lau

    Johnson Y.n. Lau, Chief Executive Officer and Board Chairman, Director

    • Jordan Kanfer

      Jordan Kanfer, Director

      • Robert J. Spiegel

        Robert J. Spiegel, Director

        • Benson Tsang

          Benson Tsang, Director

          LocationsView all

          11 locations detected

          • Buffalo, NY HQ

            United States

            Conventus, 1001 Main St #600

          • Clarence, NY

            United States

            11342 Main St

          • Cranford, NJ

            United States

            20 Commerce Dr #100

          • Houston, TX

            United States

            6200 Savoy Dr #1200

          • Schaumburg, IL

            United States

            10 N Martingale Rd #230

          • CABA

            Argentina

            piso 12, Carlos Pellegrini 713

          and 5 others

          Athenex Financials

          Summary Financials

          Revenue (FY, 2022)
          $102.8M
          Gross profit (FY, 2022)
          $26.7M
          Net income (FY, 2022)
          ($104.4M)
          Cash (FY, 2022)
          $30.4M
          EBIT (FY, 2022)
          ($70.0M)
          Enterprise value
          $14.3M

          Footer menu